Samsung Biologics
207940.KS
C$1,080
Share price
0.09%
Change (1 day)
14.60%
Change (1 year)
Categories
Revenue for Samsung Biologics (207940.KS)
Revenue in 2025 (TTM): C$4.86 Billion
According to Samsung Biologics
's latest financial reports the company's current revenue (TTM 
) is C$4.79 Billion. In 2024 the company made a revenue of C$4.73 Billion an increase over the revenue in the year 2023 that were of C$3.72 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Samsung Biologics from 2016 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | C$4.86 B | 2.71% |
| 2024 | C$4.73 B | 27.29% |
| 2023 | C$3.72 B | 19.27% |
| 2022 | C$3.11 B | 81.28% |
| 2021 | C$1.72 B | 33.85% |
| 2020 | C$1.28 B | 63.25% |
| 2019 | C$0.78 B | 18.76% |
| 2018 | C$0.66 B | 25.87% |
| 2017 | C$0.52 B | 54.04% |
| 2016 | C$0.34 B |